MX2016013963A - Metodos mejorados para la elaboracion de terapias celulares adoptivas. - Google Patents

Metodos mejorados para la elaboracion de terapias celulares adoptivas.

Info

Publication number
MX2016013963A
MX2016013963A MX2016013963A MX2016013963A MX2016013963A MX 2016013963 A MX2016013963 A MX 2016013963A MX 2016013963 A MX2016013963 A MX 2016013963A MX 2016013963 A MX2016013963 A MX 2016013963A MX 2016013963 A MX2016013963 A MX 2016013963A
Authority
MX
Mexico
Prior art keywords
adoptive cell
cell therapies
improved methods
manufacturing
manufacturing adoptive
Prior art date
Application number
MX2016013963A
Other languages
English (en)
Other versions
MX370018B (es
Inventor
Morgan Richard
friedman Kevin
MAIER Dawn
Original Assignee
Bluebird Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54333268&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016013963(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bluebird Bio Inc filed Critical Bluebird Bio Inc
Publication of MX2016013963A publication Critical patent/MX2016013963A/es
Publication of MX370018B publication Critical patent/MX370018B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2301—Interleukin-1 (IL-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants

Abstract

La invención provee composiciones y métodos para elaborar terapias celulares adoptivas; en modalidades particulares, la invención proporciona métodos para cosechar las poblaciones de células, aislar y activar PBMC, expandir células T y administrar la célula T terapéutica a un sujeto que lo necesita.
MX2016013963A 2014-04-25 2015-04-24 Metodos mejorados para la elaboracion de terapias celulares adoptivas. MX370018B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461984558P 2014-04-25 2014-04-25
PCT/US2015/027518 WO2015164745A1 (en) 2014-04-25 2015-04-24 Improved methods for manufacturing adoptive cell therapies

Publications (2)

Publication Number Publication Date
MX2016013963A true MX2016013963A (es) 2017-06-12
MX370018B MX370018B (es) 2019-11-28

Family

ID=54333268

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016013963A MX370018B (es) 2014-04-25 2015-04-24 Metodos mejorados para la elaboracion de terapias celulares adoptivas.
MX2019014009A MX2019014009A (es) 2014-04-25 2016-10-24 Metodos mejorados para la elaboracion de terapias celulares adoptivas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019014009A MX2019014009A (es) 2014-04-25 2016-10-24 Metodos mejorados para la elaboracion de terapias celulares adoptivas.

Country Status (25)

Country Link
US (1) US20170051252A1 (es)
EP (2) EP3738597A1 (es)
JP (4) JP6817069B2 (es)
KR (3) KR20160141865A (es)
CN (2) CN106456670B (es)
AU (2) AU2015249376C1 (es)
BR (1) BR112016024957A2 (es)
CA (1) CA2946552A1 (es)
CY (1) CY1123142T1 (es)
DK (1) DK3134095T3 (es)
ES (1) ES2800906T3 (es)
HR (1) HRP20200978T1 (es)
HU (1) HUE049514T2 (es)
IL (2) IL248349B (es)
LT (1) LT3134095T (es)
MX (2) MX370018B (es)
NZ (1) NZ725201A (es)
PL (1) PL3134095T3 (es)
PT (1) PT3134095T (es)
RS (1) RS60544B1 (es)
RU (1) RU2741899C2 (es)
SG (2) SG11201608744VA (es)
SI (1) SI3134095T1 (es)
WO (1) WO2015164745A1 (es)
ZA (2) ZA201607175B (es)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105264127B (zh) 2013-03-15 2019-04-09 Gpb科学有限责任公司 颗粒的片上微流体处理
US10324011B2 (en) 2013-03-15 2019-06-18 The Trustees Of Princeton University Methods and devices for high throughput purification
US20150064153A1 (en) 2013-03-15 2015-03-05 The Trustees Of Princeton University High efficiency microfluidic purification of stem cells to improve transplants
CN116656605A (zh) 2014-04-16 2023-08-29 朱诺治疗有限公司 用于扩增细胞群的方法、试剂盒及装置
US11400115B2 (en) 2014-04-23 2022-08-02 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
SG11201608754SA (en) 2014-04-25 2016-11-29 Bluebird Bio Inc Mnd promoter chimeric antigen receptors
BR112016028644B1 (pt) 2014-06-06 2019-12-03 Bluebird Bio Inc Método in vitro ou ex vivo para fabricar células t, composição compreendendo um agente de crioproteção e uma população de células efetoras imunes e usos terapêuticos dadita composição
ES2878449T3 (es) 2014-07-24 2021-11-18 2Seventy Bio Inc Receptores antigénicos quiméricos de BCMA
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
AU2015360845B2 (en) 2014-12-12 2020-11-26 2Seventy Bio, Inc. BCMA chimeric antigen receptors
EP3240803B1 (en) 2014-12-29 2021-11-24 Novartis AG Methods of making chimeric antigen receptor-expressing cells
EP3283619B1 (en) 2015-04-17 2023-04-05 Novartis AG Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
EP3466967A1 (en) 2015-05-18 2019-04-10 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
FR3038324B1 (fr) 2015-06-30 2020-10-30 Lab Francais Du Fractionnement Procede de cryoconservation de cellules a visee therapeutique
EP3325504A1 (en) 2015-07-21 2018-05-30 Novartis AG Methods for improving the efficacy and expansion of immune cells
US10976232B2 (en) 2015-08-24 2021-04-13 Gpb Scientific, Inc. Methods and devices for multi-step cell purification and concentration
TWI630934B (zh) * 2015-10-14 2018-08-01 瑞典商神經毫微股份有限公司 移植醫藥設備到神經組織中的方法以及設備
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
CA3002742A1 (en) 2015-10-22 2017-04-27 Juno Therapeutics Gmbh Methods, kits, agents and apparatuses for transduction
CA3001941A1 (en) 2015-10-30 2017-05-04 Nbe-Therapeutics Ag Anti-ror1 antibodies
WO2017099712A1 (en) * 2015-12-07 2017-06-15 Bluebird Bio, Inc. Improved t cell compositions
US20190269727A1 (en) * 2015-12-28 2019-09-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
TW201736399A (zh) 2015-12-31 2017-10-16 財團法人生物技術開發中心 抗vegfr抗體及其應用
BR112018014615A2 (pt) 2016-01-20 2018-12-11 The Scripps Research Institute composições de anticorpo para ror1 e métodos relacionados
US20190161530A1 (en) * 2016-04-07 2019-05-30 Bluebird Bio, Inc. Chimeric antigen receptor t cell compositions
EP3439685B1 (en) * 2016-04-08 2023-07-05 Emory University Methods of treating cancer and infectious diseases using cell based therapies
CN105907790A (zh) * 2016-06-21 2016-08-31 林志国 特异性识别EGFRvⅢ的含CD70嵌合抗原受体修饰T细胞的制备方法
US11242376B2 (en) 2016-08-02 2022-02-08 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
ES2875959T3 (es) 2016-10-07 2021-11-11 Tcr2 Therapeutics Inc Composiciones y métodos para reprogramación de receptores de linfocitos T mediante el uso de proteínas de fusión
EP3528630A4 (en) * 2016-10-21 2020-05-13 Georgia Tech Research Corporation T-LYMPHOCYTE EXPANSION METHODS AND SYSTEMS
WO2018080997A1 (en) * 2016-10-24 2018-05-03 Gpb Scientific, Llc Deterministic lateral displacement in the preparation of cells and compositions for therapeutic uses
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
EP4035659A1 (en) 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosomes for delivery of therapeutic agents
CN110234756A (zh) * 2017-01-18 2019-09-13 F1肿瘤医学公司 转导和扩增免疫细胞的方法及其用途
EP3577134A1 (en) 2017-01-31 2019-12-11 Novartis AG Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
US11851659B2 (en) 2017-03-22 2023-12-26 Novartis Ag Compositions and methods for immunooncology
JP2020511987A (ja) * 2017-03-28 2020-04-23 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 移植された組織を拒絶反応から保護するための方法
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
CN109134660B (zh) * 2017-06-16 2022-07-01 上海恒润达生生物科技股份有限公司 靶向Mesothelin的嵌合抗原受体并联合表达抗PD1抗体的方法及其用途
CN107236762A (zh) * 2017-06-19 2017-10-10 河北浓孚雨生物科技有限公司 一种微环dna转染t细胞制备临床级car‑t细胞制剂的方法
EP3648757A4 (en) * 2017-07-03 2020-11-25 Development Center for Biotechnology ANTI-VEGFR ANTIBODIES AND USES THEREOF
SG11202000846WA (en) 2017-08-07 2020-02-27 Nbe Therapeutics Ag Anthracycline-based antibody drug conjugates having high in vivo tolerability
JP7275104B2 (ja) 2017-08-09 2023-05-17 ジュノー セラピューティクス インコーポレイテッド 遺伝子操作された細胞の組成物および関連組成物を産生するための方法
KR102296580B1 (ko) 2017-09-01 2021-09-02 론자 워커스빌 아이엔씨. 엔드-투-엔드 세포 요법의 자동화
EP3675876A4 (en) * 2017-09-01 2021-06-02 GPB Scientific, Inc. PROCESSES FOR PREPARING THERAPEUTICALLY ACTIVE CELLS USING MICROFLUIDICS
WO2019079569A1 (en) 2017-10-18 2019-04-25 Novartis Ag COMPOSITIONS AND METHODS FOR SELECTIVE DEGRADATION OF A PROTEIN
CN107893055B (zh) * 2017-11-03 2020-07-17 深圳市默赛尔生物医学科技发展有限公司 一种特异性嵌合抗原受体基因修饰的自然杀伤细胞及其制备方法和用途
US20200330983A1 (en) * 2017-11-10 2020-10-22 Juno Therapeutics, Inc. Closed-system cryogenic vessels
CN109776671B (zh) * 2017-11-14 2022-05-27 杭州康万达医药科技有限公司 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用
CA3088095A1 (en) 2017-11-15 2019-05-23 Novartis Ag Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
JP2021509009A (ja) 2017-11-30 2021-03-18 ノバルティス アーゲー Ｂｃｍａターゲティングキメラ抗原受容体及びその使用
SG11202005272SA (en) * 2017-12-08 2020-07-29 Juno Therapeutics Inc Process for producing a composition of engineered t cells
CN109609533B (zh) * 2017-12-27 2020-07-10 赛德特生物科技开发有限公司 基于人源化cd276抗体的car慢病毒表达载体构建及其应用
CN112218651A (zh) 2018-01-08 2021-01-12 诺华公司 用于与嵌合抗原受体疗法组合的免疫增强rna
CN112125976B (zh) * 2018-01-26 2022-06-03 重庆精准生物技术有限公司 改造的铰链及其在构建car骨架中的应用
WO2019152660A1 (en) 2018-01-31 2019-08-08 Novartis Ag Combination therapy using a chimeric antigen receptor
AU2019218093A1 (en) * 2018-02-09 2020-09-10 Immatics US, Inc. Methods for manufacturing T cells
DE102018108996B4 (de) 2018-02-09 2021-10-21 Immatics US, Inc. Verfahren zur Herstellung autologer T-Zellen
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
CN110272481A (zh) * 2018-03-14 2019-09-24 中国科学院广州生物医药与健康研究院 识别mage1抗原短肽的t细胞受体
EP3765121A4 (en) * 2018-03-14 2021-12-22 Thermogenesis Corp. ACTIVATION / TRANSDUCTION SYSTEMS AND PROCEDURES COMPATIBLE WITH BUILD-UP ACTIVATED CELL SORTING (BACS)
DE102018108612A1 (de) * 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
SG11202010319RA (en) 2018-04-27 2020-11-27 Iovance Biotherapeutics Inc Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
CN112424342A (zh) * 2018-05-08 2021-02-26 生命科技公司 用于培养和扩增细胞的组合物和方法
CN108929862A (zh) * 2018-08-01 2018-12-04 上海市第人民医院 一种恶性肿瘤肺转移伴恶性胸腔积液的t细胞制备与扩增方法及其应用
EP3844265A2 (en) 2018-08-31 2021-07-07 Novartis AG Methods of making chimeric antigen receptor-expressing cells
SG11202101825QA (en) 2018-08-31 2021-03-30 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
EP3876979A4 (en) 2018-11-08 2022-08-24 NexImmune, Inc. COMPOSITIONS OF T LYMPHOCYTES WITH ENHANCED PHENOTYPIC PROPERTIES
US20220017862A1 (en) * 2018-11-16 2022-01-20 Celgene Corporation Improved t cell manufacturing process
US20220033848A1 (en) * 2018-11-19 2022-02-03 Board Of Regents, The University Of Texas System A modular, polycistronic vector for car and tcr transduction
KR20210107749A (ko) 2018-12-21 2021-09-01 옥테인 바이오테크 인코포레이티드 모듈식 생물학적 생산 유닛들을 위한 캐러셀
CN113195725A (zh) 2018-12-21 2021-07-30 隆萨沃克斯维尔股份有限公司 病毒载体的自动化生产
US11773365B2 (en) 2019-02-08 2023-10-03 Lonza Walkersville, Inc. Cell concentration methods and devices for use in automated bioreactors
US20220152150A1 (en) 2019-02-25 2022-05-19 Novartis Ag Mesoporous silica particles compositions for viral delivery
WO2020191172A1 (en) * 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
WO2020191316A1 (en) 2019-03-21 2020-09-24 Novartis Ag Car-t cell therapies with enhanced efficacy
CA3135852A1 (en) * 2019-04-03 2020-10-08 Akron Biotechnology, Llc Cryopreservation and cell culture media
AU2020254699A1 (en) * 2019-04-05 2021-12-02 2Seventy Bio, Inc. Manufacturing anti-BCMA CAR T cells
US20220168389A1 (en) 2019-04-12 2022-06-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US20220251152A1 (en) 2019-04-24 2022-08-11 Novartis Ag Compositions and methods for selective protein degradation
EP4021180A4 (en) * 2019-08-29 2023-11-08 Board of Regents, The University of Texas System CELL CRYOPRESERVATION MEDIUM
US20210093669A1 (en) * 2019-09-26 2021-04-01 Nantbio, Inc. Primary T-Cell Expansion
CN110747166B (zh) * 2019-10-11 2021-07-09 厦门大学 一种外周血t细胞的体外扩增培养方法
KR20220105664A (ko) 2019-11-26 2022-07-27 노파르티스 아게 Bcma 및 cd19에 결합하는 키메라 항원 수용체 및 이의 용도
MX2022010685A (es) 2020-02-27 2022-09-23 Novartis Ag Metodos de produccion de celulas que expresan receptores de antigeno quimericos.
CN115175695A (zh) * 2020-02-27 2022-10-11 诺华股份有限公司 制备表达嵌合抗原受体的细胞的方法
MX2022013065A (es) * 2020-04-22 2022-12-08 Iovance Biotherapeutics Inc Sistemas y metodos para coordinar la manufactura de celulas para inmunoterapia especifica de acuerdo al paciente.
CA3185455A1 (en) 2020-06-11 2021-12-16 Novartis Ag Zbtb32 inhibitors and uses thereof
KR20230058427A (ko) 2020-08-21 2023-05-03 노파르티스 아게 Car 발현 세포의 생체내 생성을 위한 조성물 및 방법
WO2022229853A1 (en) 2021-04-27 2022-11-03 Novartis Ag Viral vector production system
AU2022330406A1 (en) * 2021-08-20 2024-03-07 Novartis Ag Methods of making chimeric antigen receptor–expressing cells
CN114317435B (zh) * 2021-12-30 2024-02-27 杭州芯递力生物科技有限公司 一种获得抗原特异性t细胞的方法
WO2023230512A1 (en) 2022-05-26 2023-11-30 2Seventy Bio, Inc. Compositions for maintaining lentiviral vector and uses thereof
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US6905680B2 (en) * 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
ES2162823T5 (es) 1992-08-21 2010-08-09 Vrije Universiteit Brussel Inmunoglobulinas desprovistas de cadenas ligeras.
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
AU726198B2 (en) * 1996-03-04 2000-11-02 Targeted Genetics Corporation Modified rapid expansion methods ("modified-REM") for in vitro propagation of T lymphocytes
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
ATE373078T1 (de) * 2000-02-24 2007-09-15 Xcyte Therapies Inc Gleichzeitige stimulation und konzentration von zellen
WO2002088346A2 (en) 2001-05-01 2002-11-07 National Research Council Of Canada A system for inducible expression in eukaryotic cells
AU2003202908A1 (en) 2002-01-03 2003-07-24 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
GB0224442D0 (en) * 2002-10-21 2002-11-27 Molmed Spa A delivery system
JP2006524991A (ja) * 2003-05-08 2006-11-09 エクサイト セラピーズ インコーポレーティッド 抗原特異的ｔ細胞の作製および単離の方法
AU2005250408B2 (en) * 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
EP1888758A2 (en) 2005-05-20 2008-02-20 VIRxSYS Corporation Transduction of primary cells
JP5666903B2 (ja) * 2007-05-23 2015-02-12 サンガモ バイオサイエンシーズ， インコーポレイテッド 導入遺伝子の発現を増強するための方法および組成物
SI2496698T1 (sl) 2009-11-03 2019-07-31 City Of Hope Skrajšan epiderimalni receptor faktorja rasti (EGFRt) za selekcijo transduciranih T celic
JP5947311B2 (ja) 2010-12-09 2016-07-06 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 癌を治療するためのキメラ抗原受容体改変ｔ細胞の使用
CN103502439B (zh) * 2011-04-13 2016-10-12 因缪尼卡姆股份公司 用于抗原特异性t细胞增殖的方法
MX2014010183A (es) 2012-02-22 2015-03-20 Univ Pennsylvania Composiciones y metodos para generar una poblacion persistente de celulas t utiles para el tratamiento de cancer.
CA2869562C (en) * 2012-04-11 2023-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting b-cell maturation antigen
US20130280220A1 (en) 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
KR102141259B1 (ko) * 2012-09-04 2020-08-05 셀렉티스 멀티―체인 키메라 항원 수용체 및 그것의 용도들
EP2711418B1 (en) 2012-09-25 2017-08-23 Miltenyi Biotec GmbH Method for polyclonal stimulation of T cells by flexible nanomatrices
WO2014055442A2 (en) * 2012-10-01 2014-04-10 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
ES2824024T3 (es) * 2012-10-10 2021-05-11 Sangamo Therapeutics Inc Compuestos modificadores de células T y usos de los mismos
WO2014099671A1 (en) 2012-12-20 2014-06-26 Bluebird Bio, Inc. Chimeric antigen receptors and immune cells targeting b cell malignancies

Also Published As

Publication number Publication date
AU2015249376A1 (en) 2016-11-03
RU2016145968A3 (es) 2018-11-13
CN110819595A (zh) 2020-02-21
AU2015249376C1 (en) 2019-10-31
DK3134095T3 (da) 2020-06-29
EP3134095B1 (en) 2020-04-22
RS60544B1 (sr) 2020-08-31
AU2018203687C1 (en) 2022-01-13
JP2018087254A (ja) 2018-06-07
PT3134095T (pt) 2020-07-02
IL248349B (en) 2020-08-31
EP3738597A1 (en) 2020-11-18
KR20180105733A (ko) 2018-09-28
ZA201607175B (en) 2022-08-31
CN106456670A (zh) 2017-02-22
RU2741899C2 (ru) 2021-01-29
JP6817069B2 (ja) 2021-01-20
AU2018203687A1 (en) 2018-06-21
AU2015249376B2 (en) 2018-03-08
HRP20200978T1 (hr) 2020-10-16
KR20190066089A (ko) 2019-06-12
RU2016145968A (ru) 2018-05-28
KR20160141865A (ko) 2016-12-09
US20170051252A1 (en) 2017-02-23
NZ725201A (en) 2018-05-25
HUE049514T2 (hu) 2020-09-28
IL248349A0 (en) 2016-11-30
SG11201608744VA (en) 2016-11-29
LT3134095T (lt) 2020-06-10
ZA201902286B (en) 2022-08-31
AU2018203687B2 (en) 2019-03-21
ES2800906T3 (es) 2021-01-05
EP3134095A4 (en) 2017-09-20
CN106456670B (zh) 2020-01-07
JP2022040287A (ja) 2022-03-10
PL3134095T3 (pl) 2020-10-19
CY1123142T1 (el) 2021-10-29
MX2019014009A (es) 2020-02-05
KR101988614B1 (ko) 2019-06-12
JP2020015767A (ja) 2020-01-30
SI3134095T1 (sl) 2020-08-31
EP3134095A1 (en) 2017-03-01
IL276593A (en) 2020-09-30
BR112016024957A2 (pt) 2017-10-24
WO2015164745A1 (en) 2015-10-29
CA2946552A1 (en) 2015-10-29
KR102161927B1 (ko) 2020-10-06
MX370018B (es) 2019-11-28
JP2017513891A (ja) 2017-06-01
SG10201808258SA (en) 2018-10-30
IL276593B (en) 2021-10-31
JP7012056B2 (ja) 2022-02-10

Similar Documents

Publication Publication Date Title
MX2019014009A (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
IL280743B (en) Methods for enriching and producing immune cell populations for stress treatment
IL290744A (en) Methods for the production of autologous t cells used in the treatment of b-cell malignancies and other types of cancer and preparations thereof
HK1255161A1 (zh) 用於過繼性細胞治療的工程細胞
HK1244826A1 (zh) 用於過繼細胞治療的方法和組合物
NZ726989A (en) Improved t cell compositions
IL250072A0 (en) Transgenic cells for stress cell therapy
EP3619234A4 (en) COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPIES
TR201907106T4 (tr) Bir transplant alıcısında immünosüpresif terapileri izleme yöntemleri.
MA39819A (fr) Méthodes et compositions d'immunomodulation
EP3370743A4 (en) METHODS OF PREPARING LYMPHOCYTES FOR ADOPTIVE TRANSFER THERAPY OF T-CELLS
EP3426263A4 (en) METHOD AND ARTICLE FOR THE DELIVERY OF LIVABLE CELLS IN SOLID TISSUE
MY185016A (en) Progenitor cells of mesodermal lineage
EP4292600A3 (en) Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
MY181994A (en) Immuno-modulatory progenitor (imp) cell
MX2015009106A (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
IN2015DN00143A (es)
MX365403B (es) Peptidos y metodos para usarlos.
EP2558124A4 (en) POLYSACCHARID COMPOSITIONS AND METHOD FOR USE THEREOF FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH PRECURSOR CELL MOBILIZATION
WO2014134084A3 (en) Phf20 and jmjd3 compositions and methods of use in cancer immunotherapy
EP3224350A4 (en) Modulation of sh2b3 to improve red blood cell production from stem cells and/or progenitor cells
EP4295914A3 (en) Genetically-engineered drug resistant t cells and methods of using the same
EP3645020A4 (en) COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY
MX363385B (es) Métodos para el tratamiento de enfermedad de células falciformes y otras condiciones inflamatorias.
EP3164127A4 (en) Compositions and methods to improve adoptive cell therapies

Legal Events

Date Code Title Description
FG Grant or registration